DelveInsight’s “Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Follicular Lymphoma, historical and forecasted epidemiology as well as the Follicular Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Follicular Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Follicular Lymphoma Market Forecast
Some of the key facts of the Follicular Lymphoma Market Report:
- The Follicular Lymphoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- According to the SEER database, the incidence of FL in the US is 2.6/100,000 men per year based on cases from 2015 to 2019 that have been aged appropriately. 25% of all FL cases were in stage I, 15% in stage 2, 26% in stage 3, 27% in stage 4, and 7% were in stage IV
- Approximately 90% of Follicular Lymphomas possess one or more mutations in genes involved in epigenetic regulation through histone modifications (KMT2D, CREBBP, and EZH2) and chromatin remodelling (HIST1H1B-E,ARID1A), according to a research by Perrett and Okosun (2021). KMT2D, CREBBP, and EP300 are present in 60–80%, 70%, and 15%, respectively, of FL cases
- In accordance with a research by Liu W. et al. (2021), 10–20% of patients receiving immunochemotherapy relapse after 24 months of diagnosis, and these patients fare much worse than those who do not. Low, moderate, and high risk were distributed at 36%, 37%, and 27%, respectively
- Incidence cases of Follicular Lymphoma are roughly 3,300, 2,900, 2,800, 1,700, and 2,800 in Germany, France, Italy, Spain, and the UK, respectively, according to a study by Kanas et al. (2021).
- With tremendous success over the years, businesses all around the world are diligently working towards the creation of revolutionary remedies. The management of FL is showing promise from major players like Novartis Pharmaceuticals, Genentech/Roche, Xynomic Pharmaceuticals, MEI Pharma, Epizyme, Innovent Biologics, etc.
- Some of the most eagerly anticipated new medicines that are pending approval include Kymriah (tisagenlecleucel), ME-401, Abexinostat, Tazemetostat, Parsaclisib (IBI376), and others.
- Key Follicular Lymphoma Companies: Roche, Xynomic Pharmaceuticals, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Xynomic Pharma, Eli Lilly and Company, ADC Therapeutics S.A, BeiGene, Cephalon, Epizyme, Inc., Pharmacyclics LLC., Gemin X, AbbVie, Millennium Pharma, and others
- Key Follicular Lymphoma Therapies: Mosunetuzumab, Abexinostat, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others
- The Follicular Lymphoma epidemiology based on risk analyzed that low risk, intermediate risk and high risk patients contribute to 20%, 53% and 27% of all FL cases, respectively
- The Follicular Lymphoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Follicular Lymphoma pipeline products will significantly revolutionize the Follicular Lymphoma market dynamics.
Follicular Lymphoma Overview
According to the Lymphoma Research Foundation, FL is a non-Hodgkin lymphoma (NHL) that develops from B-lymphocytes and is slow-growing or indolent. Twenty to thirty percent of NHL cases are this lymphoma subtype instances. Although some FL can grow quickly, FL is often an indolent lymphoma that grows slowly.
Get a Free sample for the Follicular Lymphoma Market Report
https://www.delveinsight.com/report-store/follicular-lymphoma-market-insights
Follicular Lymphoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Follicular Lymphoma Epidemiology Segmentation:
The Follicular Lymphoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Follicular Lymphoma
- Prevalent Cases of Follicular Lymphoma by severity
- Gender-specific Prevalence of Follicular Lymphoma
- Diagnosed Cases of Episodic and Chronic Follicular Lymphoma
Download the report to understand which factors are driving Follicular Lymphoma epidemiology trends @ Follicular Lymphoma Epidemiology Forecast
Follicular Lymphoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Follicular Lymphoma market or expected to get launched during the study period. The analysis covers Follicular Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Follicular Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Follicular Lymphoma Therapies and Key Companies
- Mosunetuzumab: Roche
- Abexinostat: Xynomic Pharmaceuticals
- ME-401: MEI Pharma
- Tisagenlecleucel: Novartis
- Parsaclisib (IBI376): Innovent Biologics
- Odronextamab: Regeneron
- Mosunetuzumab: Genetech
- Abexinostat: Xynomic Pharma
- Rituximab IV: Roche
- Atezolizumab (MPDL3280A) [TECENTRIQ]: Hoffmann-La Roche
- Enzastaurin: Eli Lilly and Company
- Loncastuximab tesirine: ADC Therapeutics S.A
- Zanubrutinib: BeiGene
- Bendamustine: Cephalon
- Tazemetostat: Epizyme, Inc.
- ibrutinib: Pharmacyclics LLC.
- Obatoclax mesylate: Gemin X
- Ibrutinib: AbbVie
- IXAZOMIB: Millennium Pharma
Discover more about therapies set to grab major Follicular Lymphoma market share @ Follicular Lymphoma Treatment Market
Follicular Lymphoma Market Strengths
- Premium-price agents with superior efficacy such as CAR-T cell therapies and kinase inhibitors are expected to dominate the B-cell NHL market
Follicular Lymphoma Market Opportunities
- Currently limited treatment options available for relapsed and refractory cases in B-cell NHL.
Scope of the Follicular Lymphoma Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Follicular Lymphoma Companies: Roche, Xynomic Pharmaceuticals, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Xynomic Pharma, Eli Lilly and Company, ADC Therapeutics S.A, BeiGene, Cephalon, Epizyme, Inc., Pharmacyclics LLC., Gemin X, AbbVie, Millennium Pharma, and others
- Key Follicular Lymphoma Therapies: Mosunetuzumab, Abexinostat, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others
- Follicular Lymphoma Therapeutic Assessment: Follicular Lymphoma current marketed and Follicular Lymphoma emerging therapies
- Follicular Lymphoma Market Dynamics: Follicular Lymphoma market drivers and Follicular Lymphoma market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Follicular Lymphoma Unmet Needs, KOL’s views, Analyst’s views, Follicular Lymphoma Market Access and Reimbursement
To know more about Follicular Lymphoma companies working in the treatment market, visit @ Follicular Lymphoma Clinical Trials and Therapeutic Assessment
Table of Contents
1. Follicular Lymphoma Market Report Introduction
2. Executive Summary for Follicular Lymphoma
3. SWOT analysis of Follicular Lymphoma
4. Follicular Lymphoma Patient Share (%) Overview at a Glance
5. Follicular Lymphoma Market Overview at a Glance
6. Follicular Lymphoma Disease Background and Overview
7. Follicular Lymphoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Follicular Lymphoma
9. Follicular Lymphoma Current Treatment and Medical Practices
10. Follicular Lymphoma Unmet Needs
11. Follicular Lymphoma Emerging Therapies
12. Follicular Lymphoma Market Outlook
13. Country-Wise Follicular Lymphoma Market Analysis (2019–2032)
14. Follicular Lymphoma Market Access and Reimbursement of Therapies
15. Follicular Lymphoma Market Drivers
16. Follicular Lymphoma Market Barriers
17. Follicular Lymphoma Appendix
18. Follicular Lymphoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services